Immunophenotypically, neoplastic cells express CD20, CD79a
, CD21 and CD35.
gene encodes the Ig-[alpha] protein expressed in B-lymphocytes.
Those lymphoma cells expressed diffuse positive immunohistochemical stain for CD20, CD79a
, CD5, and cyclin D1, but were negative for CD10, CD23, BCL6, and MUM1.
Atypical cells CD2, CD3, CD5, CD7, and TIA1 were found positive, CD20, CD79a
, and CD117 were found negative, and MPO myeloid cells were positive.
The neoplastic lymphocytes in PCFCL express B-cell markers (CD19, CD20, CD22, CD79a
, PAX5) and at least one follicle center marker, which is usually BCL6 or, less commonly, CD10 (Figure 2, D and E).
They express plasma cell markers (CD38, CD138), instead of pan B-cell markers (CD20, CD79a
) of typical DLBCL.
Immunohistochemistry studies demonstrated B cells that were positive for CD79a
and CD20 (figure 2, B).
Immunohistochemical analysis revealed that [beta]-cells expressed monotypic surface IgM, CD19, CD20, CD79a
, CD10, and BCL6, with Ki-67 proliferative fraction >95%, which were diagnostic for BL.
Commonly expressed CD markers on T-lymphocytes include CD2, CD3, CD5, CD7 while CD19, CD20, CD22, CD79a
are common markers expressed on B cell.
These genes include SERPINE2 , CD79A
, and POU2AF1.
As listed in Table 2, the adherent cells from all of the five donors in the xeno-free medium had a similar expression profile of the following cell surface markers: positive expression of CD29, CD44, CD73, CD90, and CD166 and negative expression of CD14, CD34, CD45, CD79a
, CD105, CD146, CD271, HLA-DR, SSEA-4, and Stro-1.
Immunophenotyping of bone marrow cells further supported the diagnosis of BCL, with the population testing positive for CD45, CD19, CD20, CD79a
, and HLA-DR (Figures 2 and 3); however, terminal deoxynucleotidyl transferase expression in bone marrow cells was negative.